Life Sciences Archive » May, 2017

Life Sciences - May, 2017

341 articles

• PE-Backed IPOs, Biotech Deals Push 2 Firms Ahead Of Pack
• Fed. Circ. Rules PTAB Wrongly Axed Spinal Surgery Patent
• FDA Assails Amgen's Sensipar Exclusivity Suit
• Janssen Can't Escape Bulk Of FCA Suit Over HIV Drug
• Boston Scientific, St. Jude Can't Beat UC Patent Claims
• AbbVie Tops Pharma Reputation Report, Pfizer Ranks Last
• Merck Ducks Fraud Claims In Pa. Zostavax Suits
• EpiPen Maker Says Securities Fraud Allegations Don't Add Up
• Attys Sued For Malpractice Over Tossed Novartis Suit
• Reed Smith Adds Life Sciences Partner In Chicago
• Attys Face $25K In Fees After Enbrel Suit Discovery Row
• Compliance And The Transition To Value-Based Care
• The Return Of Attorney-Conducted Voir Dire
• DaVita Investors Sue Execs Over Alleged Insurance Scheme
• Covidien Gets Dissolving Suture Suit Tossed
• FDA Warning Wire: Device Maker Too Slow To Probe Defects
• Deals Rumor Mill: Miami Marlins, Mallinckrodt, E.ON
• Pfizer Seeks 6-Year Clock, Not 2, In Tossed $8M Tax Suit
• FedEx Dropped From QR Code Patent Suit
• Pharmacist Rips Feds' 'Face-Saving' After Murder Acquittals
• Gray Matters: Identities Are Us
• Justices Won't Review Parents' Vaccine Injury Suit
• The On-Sale Bar And USPTO Practices After Helsinn
• Kimberly-Clark Wants New Trial After $454M Fraud Verdict
• Hedge Fund Fights FINRA Bid To Ditch Bogus Payout Suit
• FTC Would Shred Privilege In Aggrenox Suit, DC Circ. Told
• Family Dredges Up Pradaxa Manufacturer's Discovery Woes
• AbbVie Fights Evidence Ahead Of Testosterone Bellwether
• Intra-Cellular Hid Drug Issues Before FDA Probe, Suit Says
• The Law360 400
• Turning 50, Greenberg Traurig Tops The Law360 400
• Law360 Reveals 400 Largest US Firms
• The Firms That Grew Fastest Without Merging
• Biggest US Firms Opt For Modest Growth In Sluggish Market
• The Firms That Lost The Most Ground In 2016
• Ethicon Seeks High Court Review In $3M Pelvic Mesh Suit
• Dallas Morning News Must Face Libel Suit Over Pharma Series
• Amgen Sues FDA Over Exclusivity For Blockbuster Sensipar
• Omnicare Pays $23M To End Kickback, Medicaid Fraud Suit
• J&J's Aveeno Settles 'Natural' Labeling Suit For $6.75M
• Drug Settlement Malpractice Suits Rightly Tossed: 10th Circ.
• Instant Coffee Sex Aid Recalled After Report Of Death
• Consumer Agrees To Dismiss Suit Over CVS Vitamins
• Bard Ends 97 More Suits In Pelvic Mesh MDL
• J&J Hit With $2.16M Verdict In 4th Philly Mesh Case
• Fed. Circ.'s Approach To Unexpected Results In Pharma Cases
• TC Heartland Adds To Fed. Circ. Losing Streak At High Court
• FDA Chief Vows Action On Generic Approvals, Obstruction
• Pharma Cos. Say No Fraud Claimed In Cancer Drug Size Suit
• Zimmer Knee Implant Cases Will Move Forward As MDL
• Deals Rumor Mill: Staples, Web.com, Stada
• GSK Seeks New Trial In Reed Smith Atty Suicide Case
• Teva To Pay $1.6M To Resolve Calif. Counties' Opioid Suit
• My Milkshake Is Better Than Yours: Part 2
• Drug Wholesalers Blast Forest's Bid For Profit Docs
• Chinese Cos. Buy Condom, Sexual Wellness Biz For $600M
• Pfizer Says Expert Testimony In Celebrex Suit Unreliable
• Biogen Asks Judge To Toss Neurological Drug Antitrust Suit
• Michigan Law Correctly Applied In Stryker Noncompete Suit
• Extending Omnicare Beyond The Section 11 Case
• The Next Steps For Biometrics Legislation Across The US
• UC, Medivation Settle Drug Royalty Row On Eve Of Trial
• Ex-Heritage Execs To Help States Probe Drug Price-Fixing
• Theranos Dodges Investors' 'Boundless' Docs Bid, For Now
• Judge Won't Wade Into Mich. Biopharma Co.'s Proxy Fight
• PTAB Finds University Of Md. Is Immune From IP Review
• Novo Nordisk, Benefit Co. Conspired To Hike Prices, Suit Says
• 3rd Circ. Ends Amarin Shareholder Row Over Heart Drug
• My Milkshake Is Better Than Yours: Part 1
• Jury Readies To Mull 4th Philly Pelvic Mesh Case
• Costco, NBTY Can't Shake Supplement Label Row, Court Told
• Bristol-Myers, Pfizer Made Faulty Blood Thinner, Suit Says
• Mylan, IRS Ink Deal To Avoid Trial On Nebivolol Transaction
• State AGs Announce $33M Deal With J&J Over OTC Drugs
• A Potent Weapon For Fighting False Ad Claims At 9th Circ.
• FDA Delivers 1st Drug Promo Rebuke Under Trump
• Depakote Ingredient Causes Spina Bifida, Expert Tells Jury
• AIA Trial Institution Rates Are Good News For Patent Owners
• Plaintiffs Bar Perspective: Ratzan Law Group's Stuart Ratzan
• Patients Slam Bayer, Janssen's Bid To Cut Xarelto Claims
• Abbott's Depakote 'Most Toxic' Drug For Fetuses, Jury Told
• FDA Warning Wire: Pharma Staff Kept Info 'In Their Heads'
• Korean Ultrasound Co. Must Pay $3M Arbitration Award
• Lilly's $20M Cialis Patent Verdict Stayed During Appeal
• Generic Drug Price-Fixing MDL Fuels Worries For Defendants
• Deals Rumor Mill: Sinochem, Constellation, Delivery Hero
• Back To The Fourco: High Court's New, Old Patent Venue Test
• Latest J&J Pelvic Mesh Injury Case Kicks Off In Philly
• Judge Greenlights Merck's $60M Deal In Pay-For-Delay MDL
• 40 States Defend Power To Bring Generic-Drug Price-Fix Suit
• Benicar MDL Judge Dismisses Doc Accused Of Malpractice
• Zeltiq's Disclosures Mooted Suit, But Not Fees, Investor Says
• UK Watchdog Accuses Merck Of Arthritis Drug Scheme
• Attorneys, Your Input Is Needed On Deposition Rule
• Learning From Social Media For Adverse Event Reporting
• Bayer Seeks To Collect $455M Award In Dow Patent Row
• Damage Calculations Trimmed In Provigil Pay-For-Delay Row
• 5 Key Debates Over FDA's Interchangeable-Biosimilar Views
• 3 Takeaways From The Supreme Court's Patent Venue Ruling
• Attorneys React To Supreme Court Patent Venue Ruling
• Trade Secrets Suit Based On Forged Letter, Pharma Co. Says
• Roxane Owes $2M In Attys' Fees In 'Exceptional' Patent Row
• Concert Pharma Gets 2nd FTC Request Over Vertex Deal
• Investors Target NewLink Execs Over Failed Cancer Vaccine
• Buyers Want GSK, Teva To Cough Up Info In Lamictal Suit
• The EDTX Exodus: How TC Heartland Narrowed IP Venues
• Stolen Trade Secrets Cost Pharmacy $2M Per Month, Suit Says
• Shkreli Wins Grand Jury Subpoenas In Securities Fraud Suit
• Morgan Lewis Adds Corporate, Transactional Attys In Houston
• Pharma Co. Says Rosen Firm's Conflicted In Stock Drop Case
• Kirkland, Paul Weiss Assist On $446M Sale Of Nutraceutical
• 2 Rules For Avoiding Cannabis-Related Property Traps
• The Supreme Court Puts Personal Jurisdiction On Trial
• Opinions Of Counsel Post-Halo: Lessons From 16 Cases
• High Court Limits Where Patent Suits Can Be Filed
• IRS Looks To Enforce Teva Summons In Charity Inquiry
• NJ Drug Co. Dodges Class Action Over FDA Approval Claims
• 3rd Circ. Questions Early End To Lipitor Pay-For-Delay Suit
• Target, Wal-Mart Can't Dodge Herbal Supplement MDL Claims
• Investors Drop Suit Over $204M Derma Sciences Merger
• Supplement Co. Says Rival Sells Carcinogenic Products
• Hospira Comes Out $40K Ahead In Verdict Against GSK
• Fed. Circ. Upholds Injunction In Mylan Dye Patent Case
• Part Of Apriso Patent Nixed In IPR With Hedge Fund Ties
• Taxation With Representation: Skadden, Wachtell, Vinson
• Sanctions ​And Export Control Risks For Health Care Cos.
• Arix Bioscience Leads $65M Funding Round For Iterum
• Steward To Create US Hospital Operating Giant With IASIS Buy
• Health Hires: Burns & Levinson, Nossaman
• Recognizing The Fallacy Of 'Right To Try' Legislation
• Ariz. Appeals Court Tosses 'Dirty' Medical Device Suit
• CIT Grants Duty-Free Status To Some Compression Garments
• Patent Litigator Joins Quinn Emanuel From Kirkland & Ellis
• 7th Circ. Tells Eli Lilly To Restore Ill Worker's Benefits
• 3rd Circ. Could Up Ante For Buyers In Pay-For-Delay Cases
• How Client Feedback Programs Benefit Law Firms And Clients
• $330M Award Against Czech Republic OK'd In Luxembourg
• Drugmaker Says Middleman Overbilled It For Services
• Lilly Ordered To Pay Jury's $20M Cialis Patent Verdict
• Chinese Educator, Dutch Biotech Raise $258M In US IPOs
• Mylan, Pfizer Say EpiPen Antitrust Suits Don't Need MDL
• 'Natural' Sex Drugs Hide Harmful Ingredients, Suit Says
• A Look At 1st-Party Insurance Coverage For Cannabis
• GSK Makes $24M Demand As Hospira Trial Wraps
• Shkreli Loses Bid To Suppress Docs In Securities Fraud Case
• Cook Medical Wins Bid To Trim Vein Filter Claims Before Trial
• Pfizer, La. End Neurontin Antitrust Suit With $1M In Naloxone
• PTAB Invalidates Humira Patent In Coherus Challenge
• Medtronic Ordered To Pay $23.5M In Patent Infringement Case
• Bipartisan Bill Again Calls For Transparency In Settlements
• Fed. Circ. Won't Put $455M Bayer Patent Award On Hold
• Express Scripts Says Kaléo Owes $14.5M In Naloxone Rebates
• Foreign Boehringer Units Look To Ax Aggrenox MDL Claims
• G1 Therapeutics Raises $105M In IPO Guided By Mintz Levin
• Lead Plaintiff Swap Doesn't Cost $37K, Counsel Says
• Zimmer Attacks Breakup Bid In Knee-Replacement MDL
• How Brazil's Corruption Crackdown Affects Health Care
• Uncertainty In Patent Term Extension For Biologics
• Privacy, Security And The Internet Of Medical Things
• AIPLA Proposes Bill To Overhaul Patent-Eligibility Law
• FDA Warning Wire: Drug Ingredients In Soda Bottles
• 6 Sentenced In $172M Health Insurance Fraud Scheme
• Ex-InterMune Director Barred From Boards For Insider Trading
• Legislation Could Ease Litigation On Fla. Medical Pot Laws
• Amputation Risk Leads To Boxed Warning On Diabetes Drugs
• Express Scripts Won't Get Quick Win Redo In Breach Suit
• Valeant, Pershing Square Balk At Draft Class Action Notices
• Kimberly-Clark Dodges Injunction After $454M Fraud Verdict
• Merck Seeks OK For $60M Settlement In Pay-For-Delay Row
• PE-Backed Cable Giant WideOpenWest Launches $400M IPO
• Using High Court's Failure To Define 'Component' In Promega
• Solving The Legal Industry's Data Protection Breakdown
• Ex-InterMune CEO Says Expert Would Have Changed Verdict
• 26 States Rejoin FCA AstraZeneca Suit Over Seroquel
• Ex-Katten Atty Looks To Gut Indictment In Shkreli Case
• 3 Firms Get $27M Payday In Elan Investors' SAC Capital Suit
• Sanofi Fights Bid To Combine EpiPen Suits Against Mylan
• Deals Rumor Mill: Stada, Ticketfly, Indigo
• Generics Copied Reckitt's Cough Drug Patents, Court Told
• Medtronic Settles Heart Valve Patent Suit After Venue Fight
• Energy MLP, Cancer-Focused Biotech File IPOs Totaling $200M
• Thermo Fisher Readies $7.2B Patheon Buy
• 5 Things To Know About Justice Gorsuch's First 30 Days
• 1st Circ. Upholds Biogen's Win In Drug Sales Forecast Suit
• Ex-NFLer Says Biz Fired Him For Reporting Harassment
• Why Florida Pharmaceutical Compounders Should Be Wary
• Justices Reject Sheller Appeal Over Risperdal FDA Petition
• EU Antitrust Watchdog Probes Aspen's Cancer Med Pricing
• Forest Wants At Least $6M In Fees After Atty Misconduct
• Ex-WilmerHale IP Atty Returns To Wolf Greenfield
• 'Pre-Approval' Design Defects? There's No Such Thing
• Judge Says Pfizer's $8.3M Tax Suit Brought Too Late
• 5 Mistakes That End Law Firms
• Fed. Circ. Denies Dow Review Of $455M Bayer Patent Award
• Miss. Wants Medicare Reimbursement Suit In State Court
• Foundation Asks For Treble Damages In Hearing Aid IP Case
• 4 Firms To Lead 3 IPOs Raising $300M, Led By Biotech Cos.
• Ex-MLB Player DeCinces Convicted In Insider Trading Case
• Shkreli Probe Not Finished, Prosecutor Tells NY Trial Judge
• Candela Can't Nix Surgeon's Suit Over Weight Reduction Tool
• Taxation With Representation: Debevoise, Sullivan, Fried
• What Braintree Means For Intent To Induce Infringement
• Kerr Russell Cops To Aiding Eavesdropping On Depositions
• The Case For A Lawyer As Chief Operating Officer
• 9th Circ. Won't Revive Sanofi Patent FCA Suit
• Excess Insurer Says Akorn Not Covered For $20M Verdict
• Intuniv Buyers Fight Actavis Bid To Nix Pay-For-Delay Suit
• Drug Wholesaler Gets 5 Years In Prescription Meds Fraud
• Bio-Rad Can't Get New Trial Over $8M Jury Verdict For Ex-GC
• Amgen Patent Suit Targets Coherus' Neulasta Biosimilar
• Clovis Shareholder Sues Over Directors' Lofty Pay
• Complicated Landscape Awaits New FDA Commissioner
• A Guide To Competitive Marijuana Licensing Applications
• Patenting An Interface Between Human Brain And Computer
• GE, Infant Product Co. Reach Deal In Incubator Patent Case
• Cherokees' Opioid Suit A Test For Tribal Courts' Reach
• Novartis Says Gleevec Antitrust Suit Should Remain Paused
• 5 Top Priorities As Gottlieb Takes Reins At FDA
• Watson Seeks Quick Win In Suit Over FTC Litigation Powers
• Astellas Sues Roxane Over Generic Cancer Drug ANDA
• Solomon Gets Nearly $5M In Spirogen Sale Dispute
• Fraudster Must Pay $130.2M In Restitution, Fla. Judge Says
• Texas Suit Over Death Penalty Drug Faces Steep Odds
• MDL Lead Attys Face Class Action Over Dismissed Yaz Suits
• Pharma Co. Dodges Shareholder Suit Over Failed Antibiotic
• 6 Habits Of A Successful Tech Lawyer
• Fed. Circ. Affirms PTAB's Invalidation Of NuVasive Patents
• Pfizer Settles Fee Dispute In $785M FCA Deal
• Vitamin Shoppe Sued Over Supplement's Weight Loss Claims
• Value-Based Health Care: 10 Things Investors Should Know
• Mylan's 3rd Circ. Doryx Loss A Hurdle To Product-Hop Suits
• INC Research, InVentiv Ink $7.4B Tie-Up
• Test Strip Makers Agree On Sanctions For Eavesdropping
• Robins Kaplan Partner Departs To Open IP Boutique In NYC
• Questioning The Controlled Substances Act After Enmon
• How China Became An IP Superpower
• Rare Grable Removal Sighted In Missouri
• Mylan, IRS Trade Opening Shots Ahead Of $100M Tax Trial
• Ill. Mom Says Ind. Time Limits Don't Apply In Depakote Case
• Ex-Lutonix VP Pleads Guilty To Trade Secret Theft
• FDA Warning Wire: Inspection Foiled By Fishy Worker Strike
• Bristol-Myers, Pfizer Escape Suit Alleging Eliquis Risks
• 4th Circ. Backs Boston Scientific Win In Pelvic Mesh Suit
• Trump Pick For FDA Commissioner Approved By Senate
• Pharmacist Gets Prosecutor's Evidence During Acquittal Bid
• Shire Loses Fed. Circ. Appeal In Generic Infringement Suit
• Feds Hit Back At Shkreli's Password-Cracking Allegations
• Wilson Sonsini Snags Former Del. Supreme Court Justice
• Third Of Approved Drugs Need Safety Follow-Up, Study Finds
• Expect Change At The Consumer Product Safety Commission
• J&J Discloses Fed. Probes Over Arthritis Drugs, Copayments
• Eyelid Scrub Maker Loses Bid To Block Walgreen Products
• Kimberly-Clark Fights Injunction After $454M Fraud Verdict
• Biotech Investor Wants Details Of Stock Swap Plan
• Medtronic Fights Extra Damages In $17M Infringement Case
• Zimmer Implant MDL Plaintiffs Seek Return To Home Courts
• Boston Scientific Looks To Dodge Mo. Pelvic Mesh Cases
• Class Cert. Denied In TCPA Suit Against Medical Supply Co.
• Trustee Drops Unilife Bonus Plan Fight After Testimony
• Takeda, Generics Push To Toss Actos Buyers' Antitrust Suit
• Deals Rumor Mill: Toshiba, Parexel, Kinder Morgan
• GSK Seeks To Strike Fraud Claims In Zofran MDL
• Pa. Court Upholds Pfizer Win In Zoloft Birth Defect Suit
• The ITC's Evolving Approach To Cease And Desist Orders
• AbbVie Can't Dodge Consumers' Claims In Testosterone MDL
• FDA Rejects Vaginal Pain Treatment
• Arizona's Off-Label Promotion Law May Hinge On Gottlieb
• 3 Cos. Launch IPOs Totaling $300M Led By Biotech Firms
• NuVasive Asks Fed. Circ. To Revive Spinal Surgery Patents
• J&J Opens 4th Pelvic Mesh Trial In Philadelphia
• Feds Chide Meningitis Fraudster's 'Unhinged' Acquittal Bid
• Protecting Privilege, Work-Product During Investigations
• 9th Circ. Sets New Falsity Standard, Citing Omnicare
• Jury Clears Zimmer In Hip-Implant Suit
• USTR Pick To Move Forward Next Week, McConnell Says
• 2 Cos. Price IPOs Totaling $285M Led By KKR-Backed REIT
• FDA Leaders Dish On Agency Policies Under Trump
• Pharma Tries To Nix Shareholder Suit Over Failed Antibiotic
• Fed. Circ. Undoes Breckenridge Generic Laxative Patent Win
• 8th Circ. Tosses FCA Suit Over Drug Price Inflation
• Retrophin Slams Shkreli's Move For Katten Muchin Docs
• Amphastar Fights Momenta, Sandoz Bid To Duck Antitrust Suit
• Animal Feed Company Must Stop Making Medicated Feeds
• Simpson, Kirkland Steer $6.4B Laboratory Products Merger
• Sanofi Escapes Health Plans' 'Deficient' Kickback Suit
• Fraudsters Owe $130M In $175M Insurance Scheme, Feds Say
• US Trustee Takes Aim At Unilife's $1M Exec Bonus Plan
• Feds Want Up To 10 Years For Wholesaler In Rx Fraud Scheme
• 3 Takeaways From First Xarelto Trial
• AbbVie Investors Sue In Chancery Over $55B Shire Merger
• J&J Hit With $110M Verdict In Latest Mo. Talc Cancer Trial
• IHS Details Steps To Fight Opioid Crisis Among Tribes
• Unilife Gets Approval For Company Sale In Del. Ch. 11
• Theranos Shrugs Shoulders On Adding Funds To Investor Suit
• Syngenta Fights Consolidation Bid For GMO Corn Cases
• Eli Lilly Cleared To Sue Cialis Counterfeiter
• Forest Blasts Bid For Namenda Patent Litigation Docs
• EU Urged To Probe Gilead, Novartis, Roche, Aspen Pricing
• Congress Should Increase Penalties On Internet Pharmacies
• Lab Services Market Remains Ripe For Private Equity
• 13 FCPA Enforcement Actions Resolved In 2017 So Far
• Jury Asked To Punish 'Reprehensible' J&J In Talc Cancer Row
• Mylan Won't Appeal 3rd Circ. Loss On Doryx Generic
• 10th Circ. Sends Part Of Clomid Defect Suit Back To Utah
• Fed. Circ. Suggests AIA May Not Have Weakened On-Sale Bar
• 11th Circ. Gives Ex-DePuy Exec 2nd Shot At Noncompete
• Generic-Drug Makers Want 40-State Price-Fix Suit Dropped
• J&J Asks 5th Circ. To Toss $151M Hip Verdict Over Expert Pay
• Halt Medical Gets OK On Reduced Breakup Fee Proposal
• Indian Lender Can't Execute Delhi Arbitral Win Elsewhere
• Wash., NM AGs Investigating Eli Lilly's Insulin Pricing
• Bayer, Janssen Score Win In 1st Xarelto Trial
• Pa. Judge Urged To Rethink Midtrial Toss Of Risperdal Suit
• Fed. Circ. Affirms Rejection Of Cancer Therapy Patent Claims
• Akorn Hit With Derivative Suit Over $4.3B Fresenius Deal
• DOJ Raids Perrigo In Generic Drug Price-Fixing Probe
• Express Scripts Seeks Quick Win In Pharmacy Antitrust Suit
• Pfizer Must Face NYU Cancer Drug Royalties Row, Court Says
• Ex-MLB Player's Stock Deal Too Good To Be True, Jury Told
• Test Strips Seller Faces Eavesdrop Sanctions In Abbott Row
• Goldberg Segalla Adds Patent Pro As IP Chair
• FDA Warning Wire: Agency Finds Falsified Import Docs
• 10th Circ. Nixes Pot Dispensary's Challenge To IRS Probe
• Hogan Lovells Hires Pharma Partner From DEA
• Pre- And Post-AIA On-Sale Bar After Medicines And Helsinn
• Kimberly-Clark Sues Halyard Over $350M Verdict Duty Claim
• WEN Hair Care Line Bangs Out $26.3M Deal In Hair Loss Suit
• Theranos Settles $96M Investor Damage, Share Swap Suits
• Roche Ducks $25M Accutane Verdict In NJ, Gets New Trial
• What Lawyers Should Know To Avoid Online Scams
• GSK, Hospira Trade Blame For Failed Flu Vaccine Deal
• 1 Firm Grabs Spotlight Amid IPO Resurgence In April
• Escobar Ruling Helps Genentech Beat Avastin FCA Suit
• Pharmavite Reaches $1.9M Settlement Over False Ad Claims
• Valeant Securities Fraud Case Lives, Could Lose Debt Claims
• FDA Wants More Info On New Schizophrenia Drug Trials
• Shire Asks Fed. Circ. To Undo Generic's Win In Lialda Suit
• Fed. Circ. Defines Scope Of AIA On-Sale Bar Rule
• Sex Drugs Labeled As Natural Contain Viagra, Suit Says
• Negligent Undertaking Liability Only Goes So Far
• Web Servers: An Overlooked Cybersecurity Risk At Law Firms